RNN - Rexahn Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.09
-0.02 (-1.80%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.11
Open1.13
Bid0.00 x 1000
Ask0.00 x 3100
Day's Range1.05 - 1.15
52 Week Range1.03 - 2.70
Volume199,330
Avg. Volume192,269
Market Cap40.898M
Beta (3Y Monthly)2.61
PE Ratio (TTM)N/A
EPS (TTM)-0.34
Earnings DateFeb 26, 2018 - Mar 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.17
Trade prices are not sourced from all markets
  • GlobeNewswire12 hours ago

    Rexahn Pharmaceuticals Announces Leadership Transition

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve outcomes in cancers that are difficult to treat, today announced that Douglas J. Swirsky, who has served as Rexahn's president and chief financial officer since January 2018, has been named the company's president and chief executive officer and appointed to the company's board of directors effective immediately. Peter D. Suzdak, Ph.D., chief executive officer, has departed the company and resigned as a member of its board of directors.

  • GlobeNewswire9 days ago

    Rexahn Reports Third Quarter 2018 Financial Results

    ROCKVILLE, Md., Nov. 05, 2018 -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for.

  • GlobeNewswire28 days ago

    Rexahn Announces $7.5 Million Registered Direct Offering

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced it has entered into definitive agreements with institutional investors to purchase approximately 5.77 million shares of its common stock and warrants exercisable for up to approximately 5.77 million shares of its common stock for gross proceeds of approximately $7.5 million. The shares and warrants are being sold in units, each consisting of one share of common stock and a warrant to purchase one share of common stock, at an offering price of $1.30 per unit. The net proceeds of the offering will be used for further development of Rexahn’s lead clinical programs, including the funding of clinical development programs for RX-3117 and RX-5902, and for working capital and general corporate purposes.

  • GlobeNewswirelast month

    New Research Coverage Highlights Cognex, Spirit Realty Capital, Quanta Services, Rexahn Pharmaceuticals, CNO Financial Group, and Hawaiian Electric Industries — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswirelast month

    Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial of RX-3117 in Combination With Abraxane® in Patients Newly Diagnosed With Metastatic Pancreatic Cancer

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced preliminary safety and efficacy data from the ongoing Phase 2a clinical trial of RX-3117 in combination with Abraxane® (nab-paclitaxel) in patients newly diagnosed with metastatic pancreatic cancer. The data are being presented in a poster presentation titled “RX-3117, A Novel, Oral Nucleoside Analog, in Combination with Nab-Paclitaxel (nab-pac) in First-line Metastatic Pancreatic Cancer (met-PC): Safety, Tolerability and Preliminary Responses” at the 5th NCI Pancreatic Cancer Symposium held October 2-3, 2018 at the National Institutes of Health in Bethesda, Maryland.

  • GlobeNewswire2 months ago

    Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, will present preliminary safety and efficacy data from the ongoing Phase 2a clinical trial of RX-3117 in combination with Abraxane® in patients newly diagnosed with metastatic pancreatic cancer at the 5th NCI Pancreatic Cancer Symposium to be held October 2-3, 2018 at the National Institutes of Health in Bethesda, Maryland. The conference is being organized by the National Cancer Institute’s (NCI) Pancreatic Cancer Interest Group and The University Medical Center, Göttingen, Germany.

  • Top Ranked Momentum Stocks to Buy for September 5th
    InvestorPlace2 months ago

    Top Ranked Momentum Stocks to Buy for September 5th

    Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 5th:

  • ACCESSWIRE3 months ago

    3 Marijuana Stocks & Biotech Stocks Capitalizing on Industry Momentum

    CORAL GABLES, FL / ACCESSWIRE / August 21, 2018 / Once again the biotechnology sector is heading higher. The SPDR S&P Biotech ETF (XBI), iShares NASDAQ Biotechnology Index ETF (IBB) and Health Care SPDR ETF (XLV) are all green today. A number of these biotechnology companies both large and small have been capitalizing on the move that the sector has been making.

  • GlobeNewswire3 months ago

    Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

    Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 2 trial in patients with metastatic triple negative breast cancer (TNBC).

  • Benzinga3 months ago

    Pluristem Therapeutics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation

    With hundreds of biotech stocks all assuring big prospects, building a portfolio of truly transformative medicine makers is a feat. B. Riley FBR said it's found two winners.  The Analyst Analyst  George ...